The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
 
Zhichao Jiang
No Relationships to Disclose
 
Deng Wei
No Relationships to Disclose
 
Yongkun SUN
No Relationships to Disclose
 
Jianping Cheng
No Relationships to Disclose
 
Wen Zhang
No Relationships to Disclose
 
Chunmei Bai
No Relationships to Disclose
 
Zuoxing Niu
No Relationships to Disclose
 
Chunrong Zhu
No Relationships to Disclose
 
Rong Wu
No Relationships to Disclose
 
Xiaobing Chen
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Sheng Li
No Relationships to Disclose
 
Yingying Huang
No Relationships to Disclose
 
Jianfeng Zhou
No Relationships to Disclose
 
Shengbin Shi
No Relationships to Disclose
 
Feng Xiong
No Relationships to Disclose
 
Yun-Bo Zhao
No Relationships to Disclose
 
Liangjun Zhu
No Relationships to Disclose
 
Ai-Ping Zhou
Consulting or Advisory Role - Novartis; Pfizer